Home › Oropharyngeal Cancer › New York
Oropharyngeal Cancer clinical trials in New York
11 studies for Oropharyngeal Cancer are looking for participants at sites in New York.
Cities in New York
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- University of Rochester, Rochester
- Stony Brook University Medical Center, Stony Brook
- Wilmot Cancer Institute at Webster, Webster
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07195734BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05172245Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- Stony Brook University Medical Center, Stony Brook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07441681Integrated Cancer Repository for Cancer Research
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
- Faxton St. Luke's Healthcare, Mohawk Valley, Utica
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 11, 2026 · NCT06984861A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
- Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT05491512A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activites), East White Plains
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05307939A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT07063212Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
- New York University School of Medicine, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 6, 2026 · NCT03215719From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.